Bristol Pargluva review
Executive Summary
FDA's Endocrinologic & Metabolic Drugs Advisory Committee will review Bristol-Myers Squibb's Pargluva (muraglitazar) for treatment of type 2 diabetes mellitus on Sept. 9. The NDA (21-865) for 2.5 mg and 5 mg tablets of the dual peroxisome proliferators-activator receptor agonist has an estimated user fee deadline in October. The meeting will be held at the Holiday Inn in Silver Spring, Md. beginning at 8 a.m...